Abstract
Psoriasis is a debilitating skin disorder that affects 2% of the Caucasian population. In those with moderate-to-severe disease, treatment is challenging, with many cases ultimately proving refractory to traditional systemic therapies, such as methotrexate. For this group of patients, biologic therapies have emerged as novel, targeted approaches for management. One of these, the anti-TNF-α inhibitor adalimumab, is the focus of this article, with emphasis on its pharmacology, clinical efficacy and safety profile.
Keywords::
Financial & competing interests disclosure
RB Warren has received speakers or consulting fees from Abbott, Janssen-Cilag and Schering-Plough. CEM Griffiths has acted as a paid consultant or lecturer or has received research funding from Abbott, Janssen-Cilag, Merck-Serono, Schering-Plough and Wyeth. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.